HCAT241220P10000
- 1.85
- 0.000.00%
Health Catalyst Newsroom
J.P. Morgan Maintains Health Catalyst(HCAT.US) With Buy Rating, Cuts Target Price to $12
Health Catalyst (HCAT) Receives a Buy From J.P. Morgan
Health Catalyst Is Maintained at Equal-Weight by Stephens & Co.
Stephens Maintains Health Catalyst(HCAT.US) With Hold Rating, Raises Target Price to $9
Citi Maintains Health Catalyst(HCAT.US) With Buy Rating, Raises Target Price to $10.5
Stifel Maintains Health Catalyst(HCAT.US) With Hold Rating, Raises Target Price to $10
Health Catalyst Is Maintained at Sector Perform by RBC Capital
Health Catalyst Analyst Ratings
CCORF Maintains Health Catalyst(HCAT.US) With Buy Rating, Maintains Target Price $11
Evercore Maintains Health Catalyst(HCAT.US) With Buy Rating, Maintains Target Price $10
RBC Capital Maintains Health Catalyst(HCAT.US) With Hold Rating, Raises Target Price to $9
BTIG Maintains Health Catalyst(HCAT.US) With Buy Rating, Maintains Target Price $13
Barclays Maintains Health Catalyst(HCAT.US) With Buy Rating, Maintains Target Price $14
Barclays Sticks to Their Buy Rating for Health Catalyst (HCAT)
Evercore Maintains Health Catalyst(HCAT.US) With Buy Rating, Raises Target Price to $10
Health Catalyst Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Health Catalyst, Maintains $16 Price Target
CCORF Maintains Health Catalyst(HCAT.US) With Buy Rating, Maintains Target Price $11
J.P. Morgan Maintains Health Catalyst(HCAT.US) With Buy Rating, Raises Target Price to $13
CCORF Maintains Health Catalyst(HCAT.US) With Buy Rating, Maintains Target Price $11